AR-driven prostate cancer models are preferentially sensitive to BRD4 inhibition, since BRD4 and AR co-localise at target loci, including super-enhancers, to drive AR-mediated gene transcription [[16], [147]]. Here, BRD4 is linked to prostate cancer.